|
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The list is now growing with the report of increased frequency of inactivating mutations in the TNFAIP3 gene in MALT lymphomas expressing IG receptors encoded by the IGHV4-34 gene, particularly of the ocular adnexa.
|
28892161 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, subset 4 IGs do not bind DNA nor i or I carbohydrate antigens, common targets of IGHV4-34-utilizing antibodies in systemic lupus erythematosus and cold agglutinin disease, respectively.
|
28097289 |
2017 |
|
Stereotypic Movement Disorder
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication.<b>Experimental Design:</b> In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34-expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes.<b>Results:</b> We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets.
|
28536306 |
2017 |
|
Cold Hemagglutinin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, subset 4 IGs do not bind DNA nor i or I carbohydrate antigens, common targets of IGHV4-34-utilizing antibodies in systemic lupus erythematosus and cold agglutinin disease, respectively.
|
28097289 |
2017 |
|
Familial primary gastric lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-κB (NF-κB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-κB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3.
|
28682481 |
2017 |
|
Hairy Cell Leukemia
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
A molecularly defined IGHV4-34+ variant is also resistant whether HCL or HCLv immunophenotypically.
|
31068044 |
2019 |
|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL.
|
30617194 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL.
|
30617194 |
2019 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL.
|
30617194 |
2019 |
|
Childhood Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These include IGHV4-34, known to produce autoreactive antibodies, and IGKV3-20, a feature described in other B-cell malignancies but not yet in BL.
|
30617194 |
2019 |